Skip to content

Efficacy of Amisulpride Combined with Ondansetron versus Ondansetron Monotherapy in Preventing PONV: A Randomized Controlled Study

Efficacy of Amisulpride Combined with Ondansetron versus Ondansetron Monotherapy in Preventing PONV: A Randomized Controlled Study - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/073083
Enrollment
256
Registered
2024-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Injection Amisulpride: Patients will receive Inj. Amisulpride (5 mg) diluted with normal saline (3 ml) I.V slowly given over 1-2 minutes at the time of induction only Control Interventi

Sponsors

GMERS Medical College and Hospital Gotri Vadodara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 to 60 years, weight 40 to 80 kg, of either sex. American society of anaesthesia grading I and II. Surgery under general inhalational anaesthesia with expected duration of minimum one hour. Patients with two or more risk factors for PONV.

Exclusion criteria

Exclusion criteria: Allergy to the study drug. Pregnancy and Breastfeeding mother. Known case of Cardiac arrhythmias, Congenital QT syndrome, QTc more than 420msec. History of epilepsy, Parkinsons disease. Patients who had received Amisulpride for any other indication in two weeks before surgery or patients on antipsychotic therapy e.g. Levodopa. Patient is known case of prolactin dependent tumours e.g. pituitary gland prolactinoma, pheochromocytoma. Patients who have difficulty in expressing numerical rating scale like hearing disability, mentally challenged, dementia or psychiatric illness. Hypokalaemia serum POTASSIUM Level less than 3.0 mmol per liter. Patients who had received any emetogenic anticancer therapy in previous 4 weeks. Patients on chronic Opioid therapy.

Design outcomes

Primary

MeasureTime frame
Difference in complete response no episode of nausea and vomiting in the next 24 hour period after surgery, and no requirement for additional antiemetic rescue medication between both the groups. Timepoint: Initial 24 hours after surgery

Secondary

MeasureTime frame
Difference in incidence & severity of nausea by NRS score between both the groups. Comparing the need of rescue medication in both the groups. To assess adverse effects associated with both the groups. Timepoint: Initial 24 hours after surgery

Countries

India

Contacts

Public ContactDrDhara Tanna

GMERS Medical College and Hospital, Gotri, Vadodara

drdharatushar@gmail.com9979877486

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026